Skip to main content
. 2009 Dec 28;28(4):605–613. doi: 10.1200/JCO.2009.23.4781

Fig 3.

Fig 3.

Methylation changes at multiple time points after treatment. Average methylation changes (before and after 4 months on therapy) were compared between patients treated with decitabine (DAC) and supportive care (SUP). Methylation decreased by 11.2% in patients on DAC but increased by 20.1% in patients on SUP (P = .04 by Mann-Whitney U test). These methylation changes were then analyzed for correlation with response in 34 patients (DAC arm: two patients with complete remission [CR], three patients with partial remission [PR], four patients with hematologic improvement [HI], four patients with stable disease [SD], and one patient with progressive disease [PD]; supportive care arm: two patients with HI, six patients with SD, and 12 patients with PD). A greater decrease was observed in patients with CR or PR (40.6% ± 15.7%) compared with HI (9.8% ± 13.2%). Methylation increased by 15.4% in patients with SD and by 27.2% in patients with PD (P = .02 by Kruskal-Wallis test).